ALM201 Poster Presentation at 2017 ESMO Congress
September 4, 2017
Almac Discovery Announces ALM201 Poster Presentation at 2017 European Society for Medical Oncology Congress
Craigavon, N.I., UK, 4 Sept 2017 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, will present highlights of the safety data from the ALM201 Phase I trial at the ESMO congress in Madrid, Spain on September 8 – 12 2017.
Poster #383P is entitled “A phase I dose-escalation study of the novel peptide ALM201 in patients with advanced solid tumours”.
Aya El Helali1, Ruth Plummer2, Gordon C. Jayson3, Vicky M. Coyle1, Yvette Drew2, Nerissa Mescallado3, Noor Haris2, Andrew R. Clamp3, Janine McCann4, Richard D. Kennedy1,5, Aaron N. Cranston6, Richard H. Wilson1
Presenter: Dr Aya El-Helali
Time & Location: 11th September 2017 13:15 – 14:25 Hall B
About Almac Discovery
Almac Discovery is a research driven oncology company dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer. Almac Discovery focuses on the discovery to preclinical stage seeking to licence programmes early with a pharmaceutical partner for further development.
For more information, please visit www.almacgroup.com/discovery or e-mail firstname.lastname@example.org